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AbstrACt
Introduction A healthcare-associated infection (HAI) 
data point prevalence study (PPS) conducted in 1984 in 
Australian hospitals estimated the prevalence of HAI to be 
6.3%. Since this time, there have been no further national 
estimates undertaken. In the absence of a coordinated 
national surveillance programme or regular PPS, there is 
a dearth of national HAI data to inform policy and practice 
priorities.
Methods and analysis A national HAI PPS study will be 
undertaken based on the European Centres for Disease 
Control method. Nineteen public acute hospitals will 
participate. A standardised algorithm will be used to detect 
HAIs in a two-stage cluster design, random sample of 
adult inpatients in acute wards and all intensive care unit 
patients. Data from each hospital will be collected by two 
trained members of the research team. We will estimate 
the prevalence of HAIs, invasive device use, single room 
placement and deployment of transmission-based 
precautions.
Ethics and dissemination Ethics approval was obtained 
from the Alfred Health Human Research Ethics Committee 
(HREC/17/Alfred/203) via the National Mutual Assessment. 
A separate approval was obtained from the Tasmanian 
Health and Medical Human Research Committee 
(H0016978) for participating Tasmanian hospitals. Findings 
will be disseminated in individualised participating hospital 
reports, peer-reviewed publications and conference 
presentations.
IntroduCtIon  
Surveillance of healthcare-associated infec-
tions (HAIs) is a fundamental component 
of any infection prevention programme.1 
National HAI point prevalence studies (PPS) 
provide a ‘snapshot’ of all HAI types and are 
used to identify priority areas for action and 
inform infection prevention recommenda-
tions and policy direction.2 Many European 
countries regularly contribute HAI data to 
the European Centres for Disease Control 
(ECDC) PPS surveillance, and this is often in 
addition to existing, well-established national 
HAI surveillance programmes.3 4 
Australia’s first and only HAI PPS was 
conducted in 1984 and estimated the prev-
alence of ‘nosocomial’ infections to be 
6.5%.5 Subsequently, many local HAI surveil-
lance programmes have evolved separately, 
resulting in broad variation in activity and 
methodology to the extent that data cannot 
be reliably collated to generate national 
Australian HAI data, with the exception of 
Staphylococcus aureus bacteraemia.6–8
Despite strong support for a national 
surveillance programme,9 there has been 
no funding identified to achieve this goal. 
This means that Australian national infec-
tion prevention policy is not informed by 
sound national data, nor can national inter-
ventions be effectively evaluated. Further, 
where existence of HAI surveillance occurs 
at local hospital or State level, variations in 
strengths and limitations of this study
 ► The study is based on validated methods within the 
European Centres for Disease Control point preva-
lence study surveillance protocol, with the addition 
of device use prevalence estimates.
 ► Data from all sites will be collected by two trained 
data collectors minimising variation between sites.
 ► Restriction to adult acute inpatients in public facili-
ties limits representativeness.
 ► Some infections may be missed due to sampling 
process.
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methodologies means that it is not possible to meaning-
fully aggregate data.
We will undertake the first Australian HAI PPS in over 
30 years, the Comprehensive Healthcare Associated 
Infection National Surveillance (CHAINS) study. The 
European protocol provides a standardised methodology 
to European Member States and hospitals. The current 
version 5.3 provides a framework to develop a PPS in 
Australia.3 While based on the protocol developed by the 
ECDC, the CHAINS protocol differs in a number of areas 
including participation and recruitment criteria, and 
does not include patient-level risk factors or antimicrobial 
prescribing data.
The purpose of this study is to update our knowledge 
on the prevalence of HAIs and multidrug-resistant organ-
isms in Australia and provide stakeholders with national 
benchmarks that can be used to identify areas for improve-
ment, measure effectiveness of interventions and impor-
tantly use as a model for future national surveillance 
activities. We will also determine the prevalence of device 
use, informing future research projects and providing 
useful data for industry.
While guidelines for describing PPS protocols have not 
been published, this paper describes the study protocol 
and focuses on areas that vary from the ECDC protocol.
study objectives
The primary objectives of the CHAINS study are
1. To estimate the total prevalence of HAIs among in-
patients aged ≥18 in public acute care hospitals in 
Australia.
2. To describe the HAIs by site, type of patient, specialty, 
type of facility and geographical location.
The secondary objectives are
1. To determine the prevalence of patients
a. Managed under transmission-based precautions iso-
lation in a single room.
b. With an indwelling urinary catheter device.
c. With vascular access device(s).
d. With a multidrug-resistant organism (infection or 
colonisation).
MEthods And AnAlysIs
study design
A rolling PPS across a sample of Australian public hospi-
tals will be undertaken over a 3-month period. The PPS 
protocol is based on the ECDC standardised method-
ology for PPSs on HAIs,10 with some modifications to the 
Standard Protocol option (see below and table 1). The 
ECDC protocol was developed and tested extensively with 
reliable outcomes. It has been used across 29 European 
countries for national PPS and has also been applied in 
several non-European countries.11–13
hospital selection
Public acute care hospitals categorised as a Principal 
Referral hospital or a Group A hospital as per the Austra-
lian Institute for Health and Welfare peer groupings will 
be eligible to participate.14 These two peer groups are 
characterised by providing a broad range of services, 
include emergency and intensive care units (ICUs), and 
have larger patient volumes than other peer groups.14 
Because of anticipated heterogeneity and to maxi-
mise representation of large acute care public facilities, 
specialist hospitals (eg, maternity, cancer and paediatric 
hospitals) and private hospitals will be excluded.
Limited resources for this PPS restricts the number of 
participating hospitals to a sample of public acute care 
facilities. We will launch a call for expressions of interest 
for hospitals to participate in the study to measure the 
appetite for participation. To best meet the objectives 
of the study, 19 hospitals will be purposively selected to 
participate from those who meet the selection criteria. 
Hospital selection numbers will be approximately propor-
tional to the size of the six States and one of Territories in 
Australia (the other Territory will not be included due to 
logistical reasons).
Ward selection
In each participating hospital, all acute care inpatient 
wards will be included with the exception of
 ► Paediatric wards.
 ► Psychiatric wards (acute and non-acute).
 ► Neonatal ICUs.
 ► Rehabilitation, palliative, subacute and long-term 
care wards in acute care facilities (eg, nursing homes, 
spinal rehabilitation wards).
 ► Accident and emergency (A&E) departments 
(except for wards attached to A&E departments 
where patients are monitored for more than 
24 hours).
Patient sampling
Patients will be sampled in a two-stage cluster design, 
with a sample of patients in a sample of Principal Referral 
and Group A Hospitals. Patients will be systematically 
sampled on each eligible ward at participating hospi-
tals by randomly selecting either odd-numbered or 
even-numbered beds (50% sample). Randomisation will 
be achieved by the toss of a coin by the lead investigator 
(PLR) prior to the research assistants (RAs) visiting each 
site. If the bed is empty due to it not being used, then 
this is not counted in the denominator, and the next bed 
occupied within the random sample will be surveyed. As a 
high-risk group of interest, all patients in adult ICUs will 
be surveyed.
We estimate that we will survey 50% of patients at 
19 hospitals (estimated up to 5000 patients total). 
Assuming an intracluster correlation coefficient of 
3% and a prevalence of hospital acquired infection of 
7.5%–10%, we will be able to estimate prevalence with 
a precision of ±2.2%–2.5% (based on the 95% CI). 
Estimates of prevalence will account for the clustered 
design and oversampling in ICU (using inverse proba-
bility weighting).
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Patient selection
Consistent with the ECDC protocol, in each ward meeting 
the above inclusion criteria, all patients admitted to the 
ward before or at 08:00 on the first survey day and not 
discharged from the ward at the time of the survey will be 
eligible. In practice, this means that patients transferred in 
or out after 08:00 of the first survey day from or to another 
ward, or location outside the hospital, will not be included.
Patients who meet the following criteria on the eligible 
wards will be excluded:
 ► Patients under 18 years of age (in any hospital ward 
or unit).
 ► Patients undergoing same day treatment or surgery.
 ► Patients seen at outpatient department.
 ► Patients in the emergency room.
 ► Dialysis patients (outpatients).
data collection and management
Data collection from 19 sites across Australia will occur 
over a 3-month period from August to October 2018. A 
specific date for each hospital visit will be coordinated 
with the hospital. The location and size of the facility will 
be considered when planning visits to maximise efficiency 
of data collection.
All data will be collected by two trained RAs. As a 
condition of enrolment in the study, hospitals will be 
required to provide a hospital-based clinician, prefer-
ably a member of the infection prevention team, on the 
survey days. The role of the hospital clinician will be to 
accompany the RAs and to facilitate access to all wards 
and data.
The two RAs will be trained by the research team in 
data collection methodology and use of data collection 
tools. The RAs will also undergo competency-based assess-
ment prior to data collection. A secure online web-based 
survey tool will be accessed for data entry.
We will collect four levels of data: hospital, ward, patient 
and HAI.
Table 1 Summary of major differences in protocol
ECDC protocol Deviations Rationale
Patient inclusion and exclusion
 ► All patients admitted to the ward 
before or at 08:00 and not discharged 
from the ward at the time of survey, 
including neonates on maternity and 
paediatric wards, will be included
 ► 50% patients in acute wards and all 
intensive care unit patients
 ► Only adults ≥18 years old admitted to 
the ward before or at 08:00 and not 
discharged from the ward at the time of 
survey will be included
 ► Insufficient resources to sample 
every patient
Data collection processes
 ► Composition of the team responsible 
for data collection varied from one 
hospital to another
 ► The same data collectors will be 
collecting data for all hospitals in the 
PPS
 ► To minimise variation and maximise 
consistency in classifying infections
 ► Minimise the burden of data 
collection on participating hospitals
 ► Total time frame for data collection for 
all wards of a single hospital did not 
exceed 2 to 3 weeks
 ► Data to be collected during a one-off 
hospital visit (1–3 days)
 ► Same data collectors used across 
all facilities
 ► Smaller sample size
Patient data fields
 ► McCabe score was employed to 
classify the severity of underlying 
medical conditions
 ► No risk factor data will be collected  ► Insufficient resources to collect risk 
factor data
 ► Antimicrobial use  ► No antimicrobial use data will be 
collected
 ► Antimicrobial data already collected 
in annual point prevalence survey
Data validation
 ► Recommended sample size at the 
national level was 750 patients in 25 
hospitals
 ► Records of 100% of patients identified 
as having an infection at the first hospital 
(up to a maximum of 40) and a random 
sample of 5% of those identified as not 
having an infection will be reviewed
 ► Same data collectors used across 
all facilities
 ► Pragmatic validation within existing 
resources
 ► Validation team consisted was 
separate from the original data 
collection team
 ► Validation team members will consist of 
the chief investigators who cross-check 
the data
 ► Same data collectors used across 
all facilities
 ►  Blinded data validation 
recommended
 ► Validation team will not be blinded  ► Not practical for this study
ECDC, European Centres for Disease Control; PPS, point prevalence study.
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Hospital data
General hospital demographic data will be collected 
based on the ECDC protocol. However, the only indicator 
data similar to ECDC protocol are data on hand hygiene 
compliance and the number of infection control full time 
effective nurses. Further indicator data to be included 
are S. aureus bacteraemia rates (routinely reported to 
the Australian Health and Institute of Welfare) and ICU 
central line-associated bloodstream infection rates if avail-
able. These data will be collected prior to the visit.
Ward data
Ward demographic data will be collected on the day of 
the survey. Data on the ward specialty, total number of 
beds and number of single rooms are the same as for 
ECDC. Different to ECDC protocol will be data collected 
on the number of patients placed in single room isolation 
and the type of isolation. No other ward level data will be 
collected.
Patient data
Patient-level data is a modified version of the ECDC Stan-
dard Protocol. Two main differences are the omission of 
both risk factor data (McCabe) score and antimicrobial 
use data. The omission of risk factor data is to ensure 
patient data can be collected in a timely manner. Detailed 
antimicrobial data were omitted given that Australia has 
an annual national antimicrobial prescribing PPS, which 
allows more thorough analysis of antimicrobial use in 
Australia than what was possible in this PPS.15 As a screen 
to determine the presence of a HAI, data on the pres-
ence of fever and current antimicrobial therapy will be 
collected.
Data on the presence of a multidrug-resistant organism 
(MRO) will also be collected. These will include
 ► MRSA: methicillin-resistant S. aureus.
 ► VRE: vancomycin-resistant enterococci.
 ► ESBL: extended-spectrum β-lactamase.
 ► CPE: carbapenemase-producing Enterobacteriaceae.
 ► Clostridium difficile.
 ► Other drug-resistant gram-negative organisms.
 ► Other organisms that have been identified by the 
hospital as an MRO.
Screening for colonisation will occur according to 
local protocols by participating hospitals. The prevalence 
of colonisation will therefore represent colonisation 
as detected according to current Australian infection 
prevention practices. We will report on the local screening 
practices to assist with interpretation of the prevalence of 
colonisation.
HAI data
For each patient with a fever or currently receiving antimi-
crobial therapy, the RAs will work through an algorithm 
applying the HAI definitions in the ECDC protocol. Data 
on each HAI identified will be consistent with the ECDC 
protocol.
Data validation
Data will be assessed for completeness and accuracy at 
the first hospital to undergo the survey. Records of 100% 
of patients identified as having an infection (up to a 
maximum of 40) and a random sample of 5% of those 
identified as not having an infection will be reviewed by 
two chief investigators. Findings will be discussed with the 
research team prior to the survey proceeding.
Data analysis
The prevalence of HAI will be estimated from the 
proportion with infection in the sample (correcting for 
oversampling of ICU patients) with CIs corrected for 
the clustered design. This will be performed using the 
svy module in Stata V.14.2 (StataCorp, College Station, 
Texas, USA). The analysis will consider each hospital as a 
cluster and adjust for oversampling in ICU using inverse 
probability weights. Logistic regression will be used to 
examine factors associated with infection. These factors 
will include
 ► Location of hospital: metro, remote and so on.
 ► Age.
 ► Gender.
 ► Ward type.
 ► Intubation.
 ► Presence of peripheral vascular access device.
 ► Presence of central vascular access device.
 ► Indwelling urinary catheter.
outcome measures
The outcomes for each objective of the study are outlined 
in table 2.
Ethical considerations
The National Mutual Assessment is a system of single 
scientific and ethical review of multicentre human 
research projects in public health organisations in Austra-
lian Capital Territory, New South Wales, Queensland, 
South Australia, Victoria and Western Australia.
Any risks or harms identified and associated with the 
study will be reported to the human research ethics 
committees (HRECs). Reporting of the study and prog-
ress, including audits, will be conducted consistent with 
the requests of the HRECs. Any modification to the study 
that have ethical implications will be forwarded to the 
HRECs for approval. In the main results paper for the 
study, we will also aim to estimate the resources required 
to obtain ethics approval and site-specific authorisations.
Informed consent
A waiver of individual patient consent has been obtained 
for this study from the HRECs based on a number of 
considerations. These considerations are as follows: 
there are no interventions and no harm or discomfort 
to the patient as a result of the project; the benefits of 
the research justify any risk of harm associated with not 
obtaining consent; results of the research are not individ-
ualised or indeed patient identifiable; the study requires 
no direct involvement of patients, rather it collates 
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existing information obtained during their hospitalisa-
tion; and no new information will be obtained about indi-
vidual patients, therefore results will have no significance 
for the individual welfare of patients.
Patient and public involvement statement
There was no patient or public involvement in the devel-
opment of this study; however, the study was reviewed 
by patient and consumer representatives on the HREC. 
While results will not be provided directly to the patients 
surveyed in the study, data will be provided back to each 
participating facility and policy representatives and 
disseminated through peer-reviewed publications and 
conferences.
dissemination
Dissemination of knowledge gained from this study will 
be facilitated using a variety of modes. Each participating 
hospital will be provided with an individualised report 
highlighting their outcomes in comparison with other 
hospitals (deidentified) and aggregated data. Overall 
study findings will be presented through peer-reviewed 
publications, presentations to jurisdictional policy repre-
sentatives and relevant conferences.
discussion
There is a dearth of national HAI data in Australia. Data 
from a multicentre PPS on urinary tract infections in 
Australia estimated the HAI rate of urinary tract infection 
(UTI) was 1.4% and the catheter-associated UTI preva-
lence to be 0.9%.16 Recently, an estimate of the burden 
of HAI in Australia was generated from a systematic 
review of studies published between 2010 and 2016 and 
suggested the incidence of HAIs in Australia may be up 
to 165 000 per year.17
Although the Australian Commission for Safety and 
Quality in Health Care has a number of national initia-
tives to prevent HAI, it can be argued that these initiatives 
may be misdirected given the lack of national HAI data 
to inform and evaluate interventions. While administra-
tive data will soon be used to measure HAIs in Australia,18 
we contend that HAI surveillance cannot be adequately 
performed with this approach.19 20
The importance of reliable national HAI data in 
Australia cannot be underestimated. The CHAINS study 
is a small first step towards an improved understanding of 
the prevalence of HAIs in Australia. To identify, develop, 
implement and evaluate national HAI initiatives, reliable 
data based on validated methods must be used.
Strengths
This study has a number of strengths. First, it is based on 
established and validated methodology from the ECDC. 
Second, rather than rely on each hospital to collect 
and submit data, which is the common process in large 
Table 2 Key outcome measures
Objective Outcome measure
Primary objectives 
To estimate the total prevalence of HAIs among 
inpatients aged ≥18 in public acute care hospitals in 
Australia
Total no of patients classified as having a HAI divided by the total no of 
patients surveyed, weighted by the probability of sampling
To describe the HAIs by site, type of patient, 
specialty, type of facility and geographical location
Of the patients with a HAI, the proportion by
 ► Infection site
 ► Elective or emergency
 ► Gender
 ► Age
 ► Ward specialty
 ► Facility type
Secondary objectives 
Prevalence of patients managed under 
transmission-based precautions isolation in a single 
room
Total no of patients cared for under transmission-based precautions 
divided by the total number of patients surveyed, overall (weighted by the 
probability of sampling), by hospital, by ward specialty
Prevalence of patients with an indwelling urinary 
catheter device
Total no of patients with a urinary catheter divided by the total no of 
patients surveyed, overall, by hospital, by ward specialty
Prevalence of patients with vascular access 
device(s)
Total no of patients with a vascular access device divided by the total 
no of patients surveyed
Of those with a vascular device, the proportion by type of device, overall, 
by hospital, by ward specialty
Prevalence of patients with a multidrug-
resistant organism (infection or colonisation)
Total no of patients infected or colonised with a multidrug-resistant 
organism divided by the total no of patients surveyed
Of those with a multidrug-resistant organism, the proportion by organism, 
overall, by hospital, by ward specialty
HAI, healthcare-associated infection.
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PPS studies, this study will use the same trained and 
competent data collectors at each hospital. This greatly 
increases the likelihood of consistency in data collec-
tion and application of HAI definitions and prevents 
any subjective influences that may occur at a hospital 
level. Third, the two-stage cluster design, randomised 
sampling of patients at each facility and the inclusion of 
facilities in six of the seven Australian jurisdictions will 
provide confident estimates of the prevalence of HAI. 
Fourth, data on the prevalence of device use, single 
room placement and transmission-based precautions 
have never before been estimated in Australia and will 
generate new knowledge.
Limitations
Data collection is limited to adult acute inpatients, no 
data are being collected from hospitals within the private 
sector, and to ensure timely collection of data at each 
site, patient-level risk factor data (ie, McCabe index data) 
are not being collected. Some active HAIs may be missed 
due to the random sampling of patients and the use of 
fever or current antimicrobial therapy as a screen to 
explore the presence of HAI.
As hospitals were purposively selected rather than a 
random sample, we cannot exclude selection bias. To 
examine this, we will compare administrative and infec-
tion prevention metrics of participating hospitals with 
those of non-participating hospitals in the same peer cate-
gories. Such metrics will include state/territory location, 
remoteness area, bed numbers, presence of high-risk 
units for HAIs (eg, oncology, bone marrow transplan-
tation and solid-organ transplantation), healthcare-as-
sociated S. aureus bloodstream infection rate (cases per 
10 000 bed days) and hand hygiene compliance.
study status
Data collection is due to commence in August 2018.
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